Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

• Status: Not yet recruiting
• Trial end date: 2025-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose a single-center,assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Main Campus.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Collaborator: Merck Sharp & Dohme LLC
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• ≥18 years old

• American Society of Anesthesiologist physical status 3-4

• Scheduled for outpatient endoscopic retrograde cholangiopancreatography

Exclusion Criteria:

• Difficult Airway

• Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome)

• End stage renal disease requiring dialysis

• Pregnancy or breast-feeding

• Allergy to Fentanyl

• Allergy to Neuromuscular blocking drugs (eg: rocuronium)

• Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine)

• Allergy to glycopyrrolate